FORM 5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL **OWNERSHIP**

	OMB APPROVAL										
	OMB Number: 3235-036										
	Estimated average burden										
l	hours per response:	1.0									

Instruction 1(b) Form 3 Holdings Reported.

	. rolulligo i topo	ntou.														
X Form 4	Transactions F	Reported.	F	iled pursuant or Secti					urities Excha Company Ac		of 1934					
Name and Address of Reporting Person* Cox Russell J.					2. Issuer Name and Ticker or Trading Symbol <u>Jazz Pharmaceuticals plc</u> [JAZZ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Own V Officer (give title Other (spe				Owner
(Last) (First) (Middle) C/O JAZZ PHARMACEUTICALS PLC					3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2013						ear)	X Officer (give title Officer (specific below) EVP & Chief Commercial Officer)
CONNAUGHT HOUSE, 1 BURLINGTON RD, FL.																
				4. If Ame	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) DUBLIN 4 L2												X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(Si	ate)	(Zip)													
		Tal	ole I - Non-Der	ivative Se	curit	ies A	cquire	ed, D	isposed	of, or E	Beneficia	lly Owne	d			
Date (Month/Day/Year)			Execution) if any	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Dispose (D) (Instr. 3, 4 and 5)		r Disposed (5. Amou Securitie Benefici Owned a	ies For cially (D)	Form (D) or	rm: Direct II	7. Nature of ndirect Beneficial Dwnership	
			(wonding a				Amo	unt	(A) or (D)	Price	Issuer's				nstr. 4)	
Ordinary Shares 05/20/2013				1		M4		1,000	A \$8.2		3 54,024 ⁽¹⁾			D		
		7	able II - Deriva (e.g.,	ative Secu puts, calls								/ Owned				
1. Title of Derivative Security (Instr. 3)	2. 3. Transaction Date (Month/Day/Year) Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)			10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares					
Incentive Stock Option (right to	\$8.23	05/20/2013		4M		1,000	(2)		08/24/2020	Ordinary Shares	1,000	\$0	44,20	0	D	

Explanation of Responses:

- 1. Includes 288 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 29, 2013.
- 2. Of the ordinary shares subject to this incentive stock option, originally granted on August 25, 2010, 28,350 shares vested as of May 20, 2013, 9,350 shares vested as of January 21, 2014, and the remaining 7,500 shares vest in six equal monthly installments from February 21, 2014 to July 21, 2014.

Remarks:

/s/ Larissa Schwartz as attorney 02/12/2014 in fact for Russell Cox

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of SUZANNE SAWOCHKA HOOPER, VALERIE PIERCE, SOFIA LOU and LARISSA SCHWARTZ signing individually, the undersigned's true and lawful attorneys-in fact and agents to:

- 1) execute for and on behalf of the undersigned (a) Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder and (b) Forms 144 in accordance with Rule 144 promulgated under the Securities Act of 1933, as amended, as such Rule may be amended from time to time (or any successor rule) ("Rule 144");
- 2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Forms 3, 4, 5 or 144 (collectively, the "Forms"), complete and execute any amendment or amendments thereto, and timely file such Forms or amendments with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and
- 3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, including but not limited to executing and delivering for and on behalf of the undersigned any seller's representation letter that may be required to be submitted to any broker effecting any sale of securities issued by Jazz Pharmaceuticals plc (the "Company") for the account of the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company or any of its affiliates, assuming, any of the undersigned's responsibilities to comply with (a) Section 16 of the Exchange Act and (b) all of the applicable conditions of the Rule 144 safe harbor with respect to a sale of securities issued by the Company.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any Forms with respect to the undersigned's holdings of and

transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact shall no longer be employed by the Company or an affiliate of the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 12th day of November 2013.

/s/ Russell J. Cox

Russell J. Cox